title: A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis.
abstract: OBJECTIVE
  To evaluate the short-term efficacy and safety of topical cyclosporin A 0.05% in the treatment of patients with severe, steroid-resistant atopic keratoconjunctivitis (AKC).
  
  
  METHODS
  Multicenter, placebo-controlled, double-masked, randomized trial.
  
  
  METHODS
  Twenty-two patients with AKC refractory to topical steroid treatment.
  
  
  METHODS
  Patients were randomly assigned (1:1) to treatment with topical 0.05% cyclosporin A eyedrops or a placebo (artificial tears) for a period of 28 days, 6 times daily during the first 2 weeks and 4 times daily during the last 2 weeks.
  
  
  METHODS
  Symptoms (itching, tearing, discomfort, mucous discharge, and photophobia) and signs (bulbar conjunctival hyperemia, upper tarsal conjunctival papillae, punctate keratitis, corneal neovascularization, cicatrizing conjunctivitis, and blepharitis) of AKC recorded on the day of enrollment and at the end of the treatment period.
  
  
  RESULTS
  A composite score computed by summing the severity grade over all 5 symptoms and 6 signs of AKC for each patient indicated a greater improvement in the cyclosporin A group relative to the placebo at the end of the 4-week treatment period (P = 0.048 and P = 0.002, for symptoms and signs, respectively). No adverse effects of the treatment with cyclosporin A 0.05% eyedrops were observed.
  
  
  CONCLUSIONS
  Topical cyclosporin A 0.05% seems to be safe and have some effect in alleviating signs and symptoms of severe AKC refractory to topical steroid treatment.
authors.affiliation: The Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Maumenee Building #321, Baltimore, MD 21287-9238, USA. esakpek@jhmi.edu
authors.forename: Esen Karamursel
authors.initials: EK
authors.lastname: Akpek
authors.forename: John K
authors.initials: JK
authors.lastname: Dart
authors.forename: Stephanie
authors.initials: S
authors.lastname: Watson
authors.forename: William
authors.initials: W
authors.lastname: Christen
authors.forename: Dilek
authors.initials: D
authors.lastname: Dursun
authors.forename: Sonia
authors.initials: S
authors.lastname: Yoo
authors.forename: Terrence P
authors.initials: TP
authors.lastname: O'Brien
authors.forename: Oliver D
authors.initials: OD
authors.lastname: Schein
authors.forename: John D
authors.initials: JD
authors.lastname: Gottsch
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004351:Drug Resistance; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D012449:Safety
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine